BR0316131A - Acetil-l-carnitina para a prevenção e/ou tratamento de neuropatias periféricas induzidas por agentes anti-câncer - Google Patents
Acetil-l-carnitina para a prevenção e/ou tratamento de neuropatias periféricas induzidas por agentes anti-câncerInfo
- Publication number
- BR0316131A BR0316131A BR0316131-5A BR0316131A BR0316131A BR 0316131 A BR0316131 A BR 0316131A BR 0316131 A BR0316131 A BR 0316131A BR 0316131 A BR0316131 A BR 0316131A
- Authority
- BR
- Brazil
- Prior art keywords
- peripheral neuropathies
- carnitine
- acetyl
- prevention
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
"ACETIL-L-CARNITINA PARA A PREVENçãO E/OU TRATAMENTO DE NEUROPATIAS PERIFéRICAS INDUZIDAS POR AGENTES ANTI-CâNCER". A presente invenção refere-se ao uso de Acetil L-Carnitina ou de um sal farmaceuticamente aceitável da mesma para a preparação de um medicamento para a prevenção e/ou tratamento de neuropatias periféricas induzidas pela administração de um agente anti-câncer que induz à neuropatia periférica. Em particular, o referido agente anti-câncer é selecionado do grupo consistindo na família de compostos de platina, taxanos, da classe das epotilonas e vinca alcalóides, inibidores de farnesil transferase, talidomida, 5-fluorouracila, análogos de criptoficina, inibidores de proteassoma. O referido medicamento pode ser administrado de uma maneira coordenada a um individuo que está sofrendo das referidas neuropatias periféricas ou que se espera que sofra das referidas neuropatias periféricas. Efeitos benéficos sobre a qualidade de vida do paciente são obtidos e uma melhora no índice terapêutico do agente anti-câncer é obtida.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/292,823 US20030199535A1 (en) | 1998-07-30 | 2002-11-13 | Method for preventing and/or treating peripheral neuropathies induced by the administration of an anticancer agent |
PCT/IT2003/000656 WO2004043454A1 (en) | 2002-11-13 | 2003-10-23 | Acetyl-l-carnitine for the prevention and/or treatment of peripheral neuropathies induced by anticancer agents |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0316131A true BR0316131A (pt) | 2005-09-27 |
Family
ID=32312146
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0316131-5A BR0316131A (pt) | 2002-11-13 | 2003-10-23 | Acetil-l-carnitina para a prevenção e/ou tratamento de neuropatias periféricas induzidas por agentes anti-câncer |
Country Status (19)
Country | Link |
---|---|
US (2) | US20030199535A1 (pt) |
EP (1) | EP1562577B1 (pt) |
JP (1) | JP2006508958A (pt) |
KR (1) | KR20050075012A (pt) |
CN (1) | CN1708297A (pt) |
AR (1) | AR041947A1 (pt) |
AT (1) | ATE526958T1 (pt) |
AU (2) | AU2003283807B2 (pt) |
BR (1) | BR0316131A (pt) |
CA (1) | CA2505937C (pt) |
CY (1) | CY1112399T1 (pt) |
DK (1) | DK1562577T3 (pt) |
ES (1) | ES2374503T3 (pt) |
MX (1) | MXPA05004752A (pt) |
PL (1) | PL379244A1 (pt) |
PT (1) | PT1562577E (pt) |
SI (1) | SI1562577T1 (pt) |
TW (1) | TWI362260B (pt) |
WO (1) | WO2004043454A1 (pt) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002313817A1 (en) * | 2001-08-27 | 2003-03-10 | Advanced Cell Technology, Inc. | Trans-differentiation and re-differentiation of somatic cells and production of cells for cell therapies |
US7649006B2 (en) | 2002-08-23 | 2010-01-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
EP1767535B1 (en) | 2002-08-23 | 2009-12-02 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
ITMI20070817A1 (it) * | 2007-04-19 | 2008-10-20 | Farmacetika Ltd | Composizione farmaceutica comprendente l-carnitina ed un agente antagonista dei recettori adenosinici di membrana, loro derivati e/o sali farmaceuticamente accettabili, e uso degli stessi nella preparazione di farmaci con effetto non tossico di inibi |
JP4208036B1 (ja) * | 2007-04-26 | 2009-01-14 | 日本新薬株式会社 | 抗癌剤投与に伴う末梢神経障害抑制用医薬組成物 |
EP2191836B1 (en) * | 2007-08-31 | 2012-05-23 | Kyushu University, National University Corporation | Prophylactic or alleviating agent for peripheral nerve disorder induced by anti-cancer agent |
RU2485956C2 (ru) * | 2007-10-30 | 2013-06-27 | Трофо | Новая композиция для лечения побочных эффектов противораковой терапии |
AU2009324183A1 (en) * | 2008-12-01 | 2010-06-10 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Use of alkanoyl L-carnitine in combination with chemotherapeutic agents for the treatment of neoplasms |
CN102060722B (zh) * | 2009-05-01 | 2014-06-11 | 常州高新技术产业开发区三维工业技术研究所有限公司 | 一种含砷化合物及其制备方法和用途 |
ITPZ20130005A1 (it) * | 2013-07-05 | 2015-01-06 | Teodosio Antonio Ferrara | Metabolismo energetico e omeostasi |
US11162129B2 (en) | 2016-11-09 | 2021-11-02 | IsoPlexis Corporation | Photoprotective mixtures as imaging reagents in sequencing-by-synthesis |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4713370A (en) * | 1972-11-06 | 1987-12-15 | Felice Stephen L De | Carnitine and its use in reducing cardiac toxicity and as a synergist with cytostats |
US4599352A (en) * | 1984-03-01 | 1986-07-08 | The United States Of America As Represented By The Department Of Health And Human Services | Antineoplastic platinum (IV) complexes and compositions |
IT1196564B (it) * | 1986-08-04 | 1988-11-16 | Sigma Tau Ind Farmaceuti | Impiego di acetil l-carnitina nel trattamento terapeutico delle neuropatie periferiche |
DE69923322T2 (de) * | 1998-07-30 | 2005-12-22 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Verwendung von propionyl-l-carnitin und acetyl-l-carnitin zur herstellung von arzneimittel mit antikrebs wirkung |
-
2002
- 2002-11-13 US US10/292,823 patent/US20030199535A1/en not_active Abandoned
-
2003
- 2003-10-23 AT AT03775788T patent/ATE526958T1/de active
- 2003-10-23 BR BR0316131-5A patent/BR0316131A/pt not_active IP Right Cessation
- 2003-10-23 ES ES03775788T patent/ES2374503T3/es not_active Expired - Lifetime
- 2003-10-23 CN CNA2003801022169A patent/CN1708297A/zh active Pending
- 2003-10-23 PL PL379244A patent/PL379244A1/pl unknown
- 2003-10-23 KR KR1020057008678A patent/KR20050075012A/ko active Search and Examination
- 2003-10-23 JP JP2004551161A patent/JP2006508958A/ja active Pending
- 2003-10-23 MX MXPA05004752A patent/MXPA05004752A/es active IP Right Grant
- 2003-10-23 DK DK03775788.7T patent/DK1562577T3/da active
- 2003-10-23 EP EP03775788A patent/EP1562577B1/en not_active Expired - Lifetime
- 2003-10-23 CA CA2505937A patent/CA2505937C/en not_active Expired - Fee Related
- 2003-10-23 PT PT03775788T patent/PT1562577E/pt unknown
- 2003-10-23 SI SI200332090T patent/SI1562577T1/sl unknown
- 2003-10-23 WO PCT/IT2003/000656 patent/WO2004043454A1/en active Application Filing
- 2003-10-23 AU AU2003283807A patent/AU2003283807B2/en not_active Ceased
- 2003-10-30 TW TW092130286A patent/TWI362260B/zh not_active IP Right Cessation
- 2003-11-12 AR ARP030104151A patent/AR041947A1/es not_active Application Discontinuation
-
2006
- 2006-04-13 US US11/402,961 patent/US20060183798A1/en not_active Abandoned
-
2009
- 2009-04-08 AU AU2009201384A patent/AU2009201384A1/en not_active Abandoned
-
2012
- 2012-01-03 CY CY20121100001T patent/CY1112399T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
CY1112399T1 (el) | 2015-12-09 |
PT1562577E (pt) | 2012-01-12 |
SI1562577T1 (sl) | 2012-01-31 |
DK1562577T3 (da) | 2012-01-23 |
US20060183798A1 (en) | 2006-08-17 |
TWI362260B (en) | 2012-04-21 |
WO2004043454A1 (en) | 2004-05-27 |
AU2009201384A1 (en) | 2009-05-07 |
EP1562577A1 (en) | 2005-08-17 |
AU2003283807A1 (en) | 2004-06-03 |
ES2374503T3 (es) | 2012-02-17 |
TW200410683A (en) | 2004-07-01 |
AU2003283807B2 (en) | 2009-12-03 |
CA2505937A1 (en) | 2004-05-27 |
ATE526958T1 (de) | 2011-10-15 |
CN1708297A (zh) | 2005-12-14 |
US20030199535A1 (en) | 2003-10-23 |
CA2505937C (en) | 2011-07-26 |
KR20050075012A (ko) | 2005-07-19 |
MXPA05004752A (es) | 2005-08-02 |
PL379244A1 (pl) | 2006-08-07 |
AR041947A1 (es) | 2005-06-01 |
JP2006508958A (ja) | 2006-03-16 |
EP1562577B1 (en) | 2011-10-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Giovannitti et al. | Pharmacology of local anesthetics used in oral surgery | |
ES2395462T3 (es) | Inhibidores selectivos de la recaptación de norepinefrina-serotonina para el tratamiento del síndrome de fibromialgia, síndrome de fatiga crónica y dolor | |
MX2014010939A (es) | Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento. | |
BRPI0108380A8 (pt) | fórmulas de opióides agonistas resistentes à adulteração, método para diminuir o abuso de um opióide agonista numa fórmula de dosagem oral, método de preparação de uma fórmula de dosagem oral e método de tratamento da dor | |
CY1111088T1 (el) | Θεραπευτικη φαρμακοτεχνικη μορφη για χορηγηση τολτεροδινης με ελεγχομενη απελευθερωση | |
BRPI0712976A2 (pt) | uso de 2-aminotetralinas substituÍdas para a fabricaÇço de um medicamento para a prevenÇço, alÍvio e/ou tratamento de vÁrios tipos de dor | |
CY1112399T1 (el) | Ακετυλ-l-καρνιτινη για την προληψη και/ή τη θεραπεια περιφερικων νευροπαθειων που προκαλουνται απο θαλιδομιδη | |
WO2005065069A3 (en) | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease | |
EA003142B1 (ru) | Лекарственное средство, обладающее антидепрессивным действием, его применение и способ лечения | |
BRPI0610663A2 (pt) | uso terapêutico de nefopam e seus análogos | |
KR970061244A (ko) | 치매 치료용 약학 조성물 | |
BRPI0405657A (pt) | Método para o tratamento de insuficiência cardìaca grave e medicamento para o mesmo | |
KR970025615A (ko) | 암 전이 억제제 | |
BR112014004339A2 (pt) | suspensão oral | |
AU619420B2 (en) | Treatment of depression | |
BRPI0513806A (pt) | composição medicinal contendo remédio para diabetes | |
KR890006227A (ko) | 페놀-함유 진해성 액체 조성물 | |
JP4672257B2 (ja) | エポチロンを含む組成物およびカルチノイド症候群の治療のためのそれらの使用 | |
BRPI0415651A (pt) | métodos para tratar, prevenir, modificar e/ou administrar fibromialgia, e para reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de fibromialgia, e, composição farmacêutica | |
BR112015012497B1 (pt) | Combinações e composições farmacêuticas, seus usos, preparação combinada, e embalagem comercial | |
ES2952672T3 (es) | Tratamiento del dolor neuropático asociado a la neuropatía periférica inducida por la quimioterapia | |
JP2006508118A5 (pt) | ||
Aminoff | Basic & Clinical Pharmacology | |
ES2275619T3 (es) | Quetiapina para el tratamiento de discinesia en pacientes no psicoticos. | |
ES2459444T3 (es) | Combinación sinérgica de compuestos analgésicos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 3A ANUIDADE(S). |
|
B08G | Application fees: restoration [chapter 8.7 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 11A E 12A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |